L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes

J Neurochem. 1991 Jun;56(6):1997-2003. doi: 10.1111/j.1471-4159.1991.tb03458.x.

Abstract

L-Phosphoserine is one of the phosphomonoesters elevated in Alzheimer's disease brain and has close structural similarity to L-glutamate. This study attempts to define precisely the actions of L-phosphoserine at L-glutamate receptor subtypes. L-Phosphoserine is shown to bind to N-methyl-D-aspartate and kainic acid receptor subtypes, but not to the quisqualic acid subtype. Studies of [3H]MK-801 binding in the presence and absence of L-glutamate and glycine show L-phosphoserine to be a competitive N-methyl-D-aspartate antagonist. The IC50 of L-phosphoserine in these studies varies from 373 to 721 microM. This may indicate a physiologically relevant action of L-phosphoserine in Alzheimer's disease brain because whole brain concentrations may reach over 1 mM.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 2-Amino-5-phosphonovalerate / pharmacology
  • Alzheimer Disease / metabolism*
  • Animals
  • Dizocilpine Maleate / metabolism
  • Dose-Response Relationship, Drug
  • Glutamates / metabolism
  • Glycine / pharmacology
  • Kainic Acid / metabolism
  • N-Methylaspartate / pharmacology
  • Phosphoserine / metabolism*
  • Rats
  • Receptors, Glutamate
  • Receptors, Neurotransmitter / metabolism*

Substances

  • Glutamates
  • Receptors, Glutamate
  • Receptors, Neurotransmitter
  • Phosphoserine
  • N-Methylaspartate
  • Dizocilpine Maleate
  • 2-Amino-5-phosphonovalerate
  • Kainic Acid
  • Glycine